164 related articles for article (PubMed ID: 35405176)
1. Rare ATG7 genetic variants predispose patients to severe fatty liver disease.
Baselli GA; Jamialahmadi O; Pelusi S; Ciociola E; Malvestiti F; Saracino M; Santoro L; Cherubini A; Dongiovanni P; Maggioni M; Bianco C; Tavaglione F; Cespiati A; Mancina RM; D'Ambrosio R; Vaira V; Petta S; Miele L; Vespasiani-Gentilucci U; Federico A; Pihlajamaki J; Bugianesi E; Fracanzani AL; Reeves HL; Soardo G; Prati D; Romeo S; Valenti LV;
J Hepatol; 2022 Sep; 77(3):596-606. PubMed ID: 35405176
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease.
Pipitone RM; Malvestiti F; Pennisi G; Jamialahmadi O; Dongiovanni P; Bertolazzi G; Pihlajamäki J; Yki-Järvinen H; Vespasiani-Gentilucci U; Tavaglione F; Maurotti S; Bianco C; Di Maria G; Enea M; Fracanzani AL; Kärjä V; Lupo G; Männistö V; Meroni M; Piciotti R; Qadri S; Zito R; Craxì A; Di Marco V; Cammà C; Tripodo C; Valenti L; Romeo S; Petta S; Grimaudo S
Liver Int; 2023 Aug; 43(8):1761-1771. PubMed ID: 37088979
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
Bianco C; Jamialahmadi O; Pelusi S; Baselli G; Dongiovanni P; Zanoni I; Santoro L; Maier S; Liguori A; Meroni M; Borroni V; D'Ambrosio R; Spagnuolo R; Alisi A; Federico A; Bugianesi E; Petta S; Miele L; Vespasiani-Gentilucci U; Anstee QM; Stickel F; Hampe J; Fischer J; Berg T; Fracanzani AL; Soardo G; Reeves H; Prati D; Romeo S; Valenti L
J Hepatol; 2021 Apr; 74(4):775-782. PubMed ID: 33248170
[TBL] [Abstract][Full Text] [Related]
4. β-Klotho gene variation is associated with liver damage in children with NAFLD.
Dongiovanni P; Crudele A; Panera N; Romito I; Meroni M; De Stefanis C; Palma A; Comparcola D; Fracanzani AL; Miele L; Valenti L; Nobili V; Alisi A
J Hepatol; 2020 Mar; 72(3):411-419. PubMed ID: 31655133
[TBL] [Abstract][Full Text] [Related]
5. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
6. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
[TBL] [Abstract][Full Text] [Related]
7. Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Pelusi S; Baselli G; Pietrelli A; Dongiovanni P; Donati B; McCain MV; Meroni M; Fracanzani AL; Romagnoli R; Petta S; Grieco A; Miele L; Soardo G; Bugianesi E; Fargion S; Aghemo A; D'Ambrosio R; Xing C; Romeo S; De Francesco R; Reeves HL; Valenti LVC
Sci Rep; 2019 Mar; 9(1):3682. PubMed ID: 30842500
[TBL] [Abstract][Full Text] [Related]
8. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
[TBL] [Abstract][Full Text] [Related]
10. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
11. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
12. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.
Donati B; Dongiovanni P; Romeo S; Meroni M; McCain M; Miele L; Petta S; Maier S; Rosso C; De Luca L; Vanni E; Grimaudo S; Romagnoli R; Colli F; Ferri F; Mancina RM; Iruzubieta P; Craxi A; Fracanzani AL; Grieco A; Corradini SG; Aghemo A; Colombo M; Soardo G; Bugianesi E; Reeves H; Anstee QM; Fargion S; Valenti L
Sci Rep; 2017 Jul; 7(1):4492. PubMed ID: 28674415
[TBL] [Abstract][Full Text] [Related]
13. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD.
Corradini E; Buzzetti E; Dongiovanni P; Scarlini S; Caleffi A; Pelusi S; Bernardis I; Ventura P; Rametta R; Tenedini E; Tagliafico E; Fracanzani AL; Fargion S; Pietrangelo A; Valenti LV
J Hepatol; 2021 Sep; 75(3):506-513. PubMed ID: 33774058
[TBL] [Abstract][Full Text] [Related]
14. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease.
Nishida N; Yada N; Hagiwara S; Sakurai T; Kitano M; Kudo M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1646-53. PubMed ID: 26875698
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
16. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles.
Nachit M; Dioguardi Burgio M; Abyzov A; Garteiser P; Paradis V; Vilgrain V; Leclercq I; Van Beers BE
Eur Radiol; 2024 Mar; 34(3):1461-1470. PubMed ID: 37658893
[TBL] [Abstract][Full Text] [Related]
18. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
[TBL] [Abstract][Full Text] [Related]
19. Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression.
Hsieh YC; Joo SK; Koo BK; Lin HC; Lee DH; Chang MS; Park JH; So YH; Kim W;
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):388-397.e10. PubMed ID: 35101634
[TBL] [Abstract][Full Text] [Related]
20. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
